HELP — CYBIN INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1833141 ·
Last close
$12.59
Market Cap
$919.83M
52W High
$15.15
52W Low
$3.76
ADV30
1,724,032
Next earnings
2026-11-12

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -49,082,000 -47,819,000 259,655,000 — 17,568,000
Mar 2026 0 — -47,859,000 -46,995,000 251,166,000 157,258,000 19,377,000
Dec 2025 0 — -41,210,000 -42,668,000 290,112,000 195,128,000 16,178,000
Sep 2025 0 — -28,894,000 -33,722,000 181,246,000 83,752,000 42,250,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-133,271,000
Investing CF
$-1,363,000
Financing CF
$198,239,000
CapEx
$-1,373,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.87
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-389,535,000
Inventory
—
Receivables
$5,028,000
ST Investments
—
EBIT TTM
$-142,587,000
Pretax Income TTM
$-147,998,000
Interest Exp TTM
—
Analysts
9

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Mar 2026 0 -142,587,000 -147,998,000 251,166,000 19,377,000 231,789,000 -133,271,000
Mar 2025 0 -103,125,000 -81,607,000 179,897,000 14,900,000 164,997,000 -72,328,000
Mar 2024 0 -78,836,000 -78,080,000 302,023,000 10,096,000 291,927,000 -68,908,000
Mar 2023 0 -51,518,000 -47,490,000 53,897,000 5,663,000 48,234,000 -47,431,000
Mar 2022 — — — — — — —

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.83

Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $12.50 · spot: $12.59 · call volume: 132 · put volume: 50
Expected Move to 2026-10-16: ±$2.25 (17.87%) — implied range $10.34 – $14.84 · ATM straddle on $12.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
RIGL RIGEL PHARMACEUTICALS INC $922.04M $49.36 —
ALMS ALUMIS INC. $926.76M $7.16 —
JBIO Jade Biosciences, Inc. $912.62M $14.35 —
ANL Adlai Nortye Group Ltd. $904.51M $15.40 —
FBIOP Fortress Biotech, Inc. $936.35M $16.52 —

News headlines (Yahoo Finance, 1h cache)

Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression
2026-09-24 10:02 · Yahoo
Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board
2026-09-22 13:02 · Yahoo
Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003
2026-09-21 05:02 · Yahoo
Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances
2026-09-21 00:01 · Yahoo
Cybin (HELP) Stock May Be Trading At A Premium Despite Fresh Depression Trial Data
2026-09-25 01:14 · Yahoo
Cybin (HELP) Shares Moved, What Is Behind The Fresh Attention?
2026-09-24 14:16 · Yahoo
Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
2026-09-22 21:00 · Yahoo
Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
2026-09-21 21:15 · Yahoo
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
2026-09-21 11:30 · Yahoo
Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York
2026-09-10 11:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.